Aktis Oncology, Inc. (AKTS)
NASDAQ:AKTS
Want to see AKTS full AI Analyst Report?
Top Page
Aktis Oncology, Inc.
(NASDAQ:AKTS)
Select Model
Select Model
Rating:52Neutral
Price Target:
$23.00
â–²(13.58% Upside)
Action:N/A
Date:06/17/26
The score is held down primarily by weak financial performance—large losses, negative equity, and renewed significant cash burn—implying elevated financing and execution risk. Technicals are a notable offset with strong trend and momentum, but valuation remains constrained by unprofitability and the lack of dividend support.
Positive Factors
Revenue Growth & Gross Margin
A near-600% revenue increase coupled with strong gross margins signals meaningful product or program traction and scalable unit economics if growth persists. Sustained top-line expansion from successful clinical or commercial execution can structurally improve margins and reduce dependence on financing over several quarters.
Negative Factors
Deep Unprofitability
Extreme losses relative to revenue indicate the core business is not yet economically viable and will require substantial capital to reach breakeven. Persistently negative margins constrain reinvestment, increase reliance on external funding, and heighten execution risk across multiple quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth & Gross Margin
A near-600% revenue increase coupled with strong gross margins signals meaningful product or program traction and scalable unit economics if growth persists. Sustained top-line expansion from successful clinical or commercial execution can structurally improve margins and reduce dependence on financing over several quarters.
Read all positive factors
Aktis Oncology, Inc. (AKTS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.33B
Dividend YieldN/A
Average Volume (3M)N/A
Price to Earnings (P/E)―
Beta (1Y)2.90
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees79
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding53,404,617
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio3.39
Price to Book (P/B)-8.05
Price to Sales (P/S)181.08
P/FCF Ratio-15.96
Enterprise Value/Market Cap0.67
Enterprise Value/Revenue175.90
Enterprise Value/Gross Profit201.70
Enterprise Value/Ebitda-27.92
Forecast
1Y Price Target
$36.33Price Target Upside79.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Aktis Oncology, Inc. Business Overview & Revenue Model
Company Description
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the disc...
Aktis Oncology, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
27
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 5.10M | 6.50M | 1.49M | 0.00 | 0.00 |
| Gross Profit | 4.45M | 6.50M | 1.49M | 0.00 | 0.00 |
| EBITDA | -32.12M | -61.40M | -42.41M | -27.45M | -17.48M |
| Net Income | -33.46M | -63.73M | -43.98M | -28.64M | -17.93M |
Balance Sheet | |||||
| Total Assets | 576.80M | 264.88M | 326.18M | 122.36M | 138.32M |
| Cash, Cash Equivalents and Short-Term Investments | 538.48M | 226.79M | 297.17M | 97.86M | 128.60M |
| Total Debt | 11.58M | 11.55M | 12.01M | 13.40M | 1.77M |
| Total Liabilities | 70.69M | 411.03M | 413.98M | 168.66M | 157.55M |
| Stockholders Equity | 506.11M | -146.15M | -87.80M | -46.31M | -19.23M |
Cash Flow | |||||
| Free Cash Flow | -45.49M | -73.71M | 11.90M | -33.77M | -20.43M |
| Operating Cash Flow | -39.48M | -64.13M | 14.76M | -30.00M | -18.13M |
| Investing Cash Flow | -105.92M | 65.96M | -190.40M | -68.83M | -2.31M |
| Financing Cash Flow | 336.77M | -1.21M | 183.28M | 0.00 | 119.98M |
Aktis Oncology, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.